Cargando…

Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery

This preliminary clinical investigation of the pharmacokinetic behavior of the main metamizole (dipyrone) metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) in calves undergoing umbilical surgery is part of an already published main study. A single intravenous dose of metamizol...

Descripción completa

Detalles Bibliográficos
Autores principales: Fux, Daniela, Metzner, Moritz, Brandl, Johanna, Feist, Melanie, Behrendt-Wippermann, Magdalena, von Thaden, Anne, Baumgartner, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923478/
https://www.ncbi.nlm.nih.gov/pubmed/35290991
http://dx.doi.org/10.1371/journal.pone.0265305
_version_ 1784669679190540288
author Fux, Daniela
Metzner, Moritz
Brandl, Johanna
Feist, Melanie
Behrendt-Wippermann, Magdalena
von Thaden, Anne
Baumgartner, Christine
author_facet Fux, Daniela
Metzner, Moritz
Brandl, Johanna
Feist, Melanie
Behrendt-Wippermann, Magdalena
von Thaden, Anne
Baumgartner, Christine
author_sort Fux, Daniela
collection PubMed
description This preliminary clinical investigation of the pharmacokinetic behavior of the main metamizole (dipyrone) metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) in calves undergoing umbilical surgery is part of an already published main study. A single intravenous dose of metamizole was added to ketamine/xylazine/isoflurane anesthesia. Eight Simmental calves weighing 90 ± 10.8 kg and aged 47.6 ± 10.4 days received 40 mg/kg metamizole intravenously 10 minutes prior to general anesthesia. Blood samples were collected over 24 hours and analyzed for 4-MAA and 4-AA. Meloxicam was additionally given twice: 2.5 hours pre- and 20.5 hours postsurgically. The pharmacokinetic profile of 4-MAA was best fitted to a two-compartment model and was characterized by a fast distribution half-life and slow elimination half-life (t(½alpha) = 5.29 minutes, t(½beta) = 9.49 hours). The maximum concentration (C(max) 101.63 μg/mL) was detected at the first measurement time point 15 minutes after administration. In contrast, 4-AA showed fast, high and biphasic plasma peak concentration behavior in five calves (2.54–2.66 μg/mL after 15–30 minutes, and 2.10–2.14 μg/mL after 2–3.5 hours) with a t(½beta) of 8.87 hours, indicating a rapid distribution and subsequent redistribution from well-perfused organs. Alternatively, three calves exhibited a slower and lower monophasic plasma peak concentration (1.66 μg/mL after 6.5 hours) with a t(½beta) of 6.23 hours, indicating slow accumulation in the intravascular compartment. The maximum concentration and area under the plasma concentration curve (AUC) of 4-AA were lower than those of 4-MAA. This metabolic behavior supports our already published data on clinical monitoring and plasma cortisol concentrations (PCCs). Compared to those of saline controls, lower PCCs correspond to the t(½alpha) of 4-MAA. Data on T(max) and t(½beta) also match these clinical observations. However, further studies are required to assess the exact analgesic mechanism and potency of the metamizole metabolites in calves.
format Online
Article
Text
id pubmed-8923478
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-89234782022-03-16 Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery Fux, Daniela Metzner, Moritz Brandl, Johanna Feist, Melanie Behrendt-Wippermann, Magdalena von Thaden, Anne Baumgartner, Christine PLoS One Research Article This preliminary clinical investigation of the pharmacokinetic behavior of the main metamizole (dipyrone) metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) in calves undergoing umbilical surgery is part of an already published main study. A single intravenous dose of metamizole was added to ketamine/xylazine/isoflurane anesthesia. Eight Simmental calves weighing 90 ± 10.8 kg and aged 47.6 ± 10.4 days received 40 mg/kg metamizole intravenously 10 minutes prior to general anesthesia. Blood samples were collected over 24 hours and analyzed for 4-MAA and 4-AA. Meloxicam was additionally given twice: 2.5 hours pre- and 20.5 hours postsurgically. The pharmacokinetic profile of 4-MAA was best fitted to a two-compartment model and was characterized by a fast distribution half-life and slow elimination half-life (t(½alpha) = 5.29 minutes, t(½beta) = 9.49 hours). The maximum concentration (C(max) 101.63 μg/mL) was detected at the first measurement time point 15 minutes after administration. In contrast, 4-AA showed fast, high and biphasic plasma peak concentration behavior in five calves (2.54–2.66 μg/mL after 15–30 minutes, and 2.10–2.14 μg/mL after 2–3.5 hours) with a t(½beta) of 8.87 hours, indicating a rapid distribution and subsequent redistribution from well-perfused organs. Alternatively, three calves exhibited a slower and lower monophasic plasma peak concentration (1.66 μg/mL after 6.5 hours) with a t(½beta) of 6.23 hours, indicating slow accumulation in the intravascular compartment. The maximum concentration and area under the plasma concentration curve (AUC) of 4-AA were lower than those of 4-MAA. This metabolic behavior supports our already published data on clinical monitoring and plasma cortisol concentrations (PCCs). Compared to those of saline controls, lower PCCs correspond to the t(½alpha) of 4-MAA. Data on T(max) and t(½beta) also match these clinical observations. However, further studies are required to assess the exact analgesic mechanism and potency of the metamizole metabolites in calves. Public Library of Science 2022-03-15 /pmc/articles/PMC8923478/ /pubmed/35290991 http://dx.doi.org/10.1371/journal.pone.0265305 Text en © 2022 Fux et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fux, Daniela
Metzner, Moritz
Brandl, Johanna
Feist, Melanie
Behrendt-Wippermann, Magdalena
von Thaden, Anne
Baumgartner, Christine
Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery
title Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery
title_full Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery
title_fullStr Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery
title_full_unstemmed Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery
title_short Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery
title_sort pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923478/
https://www.ncbi.nlm.nih.gov/pubmed/35290991
http://dx.doi.org/10.1371/journal.pone.0265305
work_keys_str_mv AT fuxdaniela pharmacokineticsofmetamizoledipyroneasanaddonincalvesundergoingumbilicalsurgery
AT metznermoritz pharmacokineticsofmetamizoledipyroneasanaddonincalvesundergoingumbilicalsurgery
AT brandljohanna pharmacokineticsofmetamizoledipyroneasanaddonincalvesundergoingumbilicalsurgery
AT feistmelanie pharmacokineticsofmetamizoledipyroneasanaddonincalvesundergoingumbilicalsurgery
AT behrendtwippermannmagdalena pharmacokineticsofmetamizoledipyroneasanaddonincalvesundergoingumbilicalsurgery
AT vonthadenanne pharmacokineticsofmetamizoledipyroneasanaddonincalvesundergoingumbilicalsurgery
AT baumgartnerchristine pharmacokineticsofmetamizoledipyroneasanaddonincalvesundergoingumbilicalsurgery